Common narcolepsy symptoms such as excessive daytime sleepiness and sleep paralysis can affect how well you function during ...

For nearly 25 years, scientists believed they knew what caused the most severe form of narcolepsy. A new UCLA Health study ...

Oveporexton significantly improves wakefulness and reduces cataplexy frequency in patients with narcolepsy type 1, according to phase 3 study results.

For nearly 25 years, scientists believed they knew what caused the most severe form of narcolepsy. A new UCLA Health study ...

-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug ...

DUBLIN, Ireland, March 25, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial ...

Pitolisant is now the only treatment option not scheduled as a controlled substance that is indicated for both excessive daytime sleepiness and cataplexy in pediatric and adult patients. The Food and ...

The FDA has approved a supplemental new drug application for pitolisant (Wakix, Harmony Biosciences) for the treatment of cataplexy in children as young as 6 years with narcolepsy. Pitolisant was ...

Excessive daytime sleepiness was assessed using the Pediatric Daytime Sleepiness Scale total score. The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ...

There is no biological measure for wakefulness. In a narcolepsy clinical trial, a patient lies down in a dark lab while clinicians count the minutes until sleep comes. The average time in four tests ...